NMN vs MIB-626
Written by Aaron CuhaReviewed Sep 2026
The short answer
Store bought NMN against the drug grade NMN that was actually put through trials. MIB-626 raised blood NAD a lot in all three trials with a dummy group. It changed muscle strength, fitness, insulin response and liver fat in none of them.
- NMN people
- 94
- NMN nulls
- 3
- MIB-626 people
- 107
- MIB-626 nulls
- 2
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
4 completed trials, 94 people given it
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
4 completed trials, 107 people given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
NMNNicotinamide Mononucleotide
A pill the body turns into NAD+. It is studied for blood sugar and strength in ageing. Early studies in people show small results, and whether it can be sold as a US supplement is disputed.
Column B
MIB-626MIB-626, a microcrystalline polymorph of beta-nicotinamide mononucleotide
The only NMN product with a real set of studies in people: three studies with a dummy pill group, about 104 people in all. All three measured blood NAD and safety. It raised blood NAD a lot every time. It did not change muscle strength, fitness, how well insulin works or liver fat. In hospital patients, it did not change any marker of kidney damage or inflammation.
Side by side, on the facts we can check
| What we compare | NMN | MIB-626 |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | Not an approved drug; whether it can be sold as a US supplement is disputed | An investigational drug in the United States. Metro International Biotech is developing it under an FDA permit to test it in people (an IND). It is not approved for any use. It is the same molecule as NMN sold as a supplement, but the law treats it as a different product. That IND is what led the FDA in 2022 to rule that NMN could not be sold as a supplement. The FDA reversed that ruling in September 2025. |
| Half-life | Short | The pharmacokinetic trial measured blood NMN and NAD exposure rather than a clean elimination half-life. NMN itself clears quickly and very little unmodified NMN was recovered in urine, while the downstream NAD rise built gradually over days and peaked late in the dosing period. |
| Molecular weight | 334.2 Da | 334.2 Da. It is beta-nicotinamide mononucleotide; the proprietary part is the crystal form, not the molecule. |
| How it works | The body turns it into NAD+ through a recycling route called the salvage pathway. The aim is to bring back NAD+ levels that fall with age. | The active molecule is NMN. The body turns NMN straight into NAD in one step. That skips NAMPT, the slow step that holds back nicotinamide. What the company owns is the form, not the chemistry. It is one defined crystal form, meant to give the same dose every time, like a real drug. That is what makes dose testing and drug filings possible in a way a variable supplement powder does not. A 2026 study in people raised another possibility. NMN and NR swallowed by mouth may raise NAD partly because gut bacteria turn them into niacin. If that is right, it applies to this product as much as to any other NMN pill. |
| Studies in people | 4 | 4 |
| Evidence | Limited: 4 completed trials, 94 people given it | Moderate: 4 completed trials, 107 people given it |
| Legal status, US | Not approved; in 2022 the FDA decided it does not count as a supplement | Investigational, not approved |
Frequently asked questions
What is the difference between NMN and MIB-626?
NMN: A pill the body turns into NAD+. It is studied for blood sugar and strength in ageing. Early studies in people show small results, and whether it can be sold as a US supplement is disputed. MIB-626: The only NMN product with a real set of studies in people: three studies with a dummy pill group, about 104 people in all. All three measured blood NAD and safety. It raised blood NAD a lot every time. It did not change muscle strength, fitness, how well insulin works or liver fat. In hospital patients, it did not change any marker of kidney damage or inflammation.
Which has stronger research evidence, NMN or MIB-626?
Each compound gets a band worked out from facts we counted, with the math shown. NMN is Limited (4 completed trials, 94 people given it). MIB-626 is Moderate (4 completed trials, 107 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are NMN and MIB-626 FDA-approved?
NMN: Not an approved drug; whether it can be sold as a US supplement is disputed. MIB-626: An investigational drug in the United States. Metro International Biotech is developing it under an FDA permit to test it in people (an IND). It is not approved for any use. It is the same molecule as NMN sold as a supplement, but the law treats it as a different product. That IND is what led the FDA in 2022 to rule that NMN could not be sold as a supplement. The FDA reversed that ruling in September 2025..
Related posts
Blog articles that cover NMN or MIB-626, newest first.
- Longevity / Sep 27, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
- Metabolic / Sep 27, 2026 / 7 minSLU-PP-332 and 5-Amino-1MQ: Two 'Peptides' That Are Not Peptides, and What the Mouse Data Actually Show
- Longevity / Sep 27, 2026 / 8 minNMN vs NR vs NAD+: The 2026 Head-to-Head Human Trials, and Who Funded the Comparisons
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.